“Improvement of risk assessment in cutaneous melanoma (CM) by a prognostic 31-gene expression profile (31-GEP) test over AJCC-based staging alone” (2018) SKIN The Journal of Cutaneous Medicine, 2, p. S70. doi:10.25251/skin.2.supp.70.